Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.36 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2564954 | 0.94 | FADS1 (0.37) | HRH3KCNH2FADS1PDE10ALIPE | |
| SCHEMBL2564400 | 0.89 | FADS1 (0.35) | HRH3KCNH2FADS1PDE10ALIPE | |
| SCHEMBL2564033 | 0.89 | FADS1 (0.35) | HRH3KCNH2FADS1LIPEPIK3CD | |
| SCHEMBL2564084 | 0.89 | FADS1 (0.35) | HRH3KCNH2FADS1PDE10ALIPE | |
| SCHEMBL2563240 | 0.88 | ALDH1A1 (0.38) | HRH3KCNH2FADS1LIPEPIK3CD | |
| SCHEMBL2567951 | 0.88 | ALDH1A1 (0.42) | HRH3KCNH2FADS1LIPEPIK3CD | |
| SCHEMBL2995196 | 0.88 | FADS1 (0.33) | HRH3KCNH2FADS1LIPEPIK3CD | |
| SCHEMBL2568067 | 0.88 | FADS1 (0.37) | HRH3KCNH2FADS1LIPEPIK3CD | |
| SCHEMBL13266553 | 0.88 | MAPT (0.38) | HRH3KCNH2CYP1B1PDE10A | |
| SCHEMBL2566961 | 0.86 | HPGD (0.36) | HRH3KCNH2FADS1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | HRH3 2242/4885KCNH2 2927/4885FADS1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.